Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results
Viatris Inc. (VTRS) recently secured a ¥40 billion senior unsecured term loan to support business operations and refinance an existing loan, with interest rates tied to the TIBO rate plus 1.10% and credit ratings. This financial move follows positive Phase 3 results for its drug Nefecon in a Japanese trial for primary immunoglobulin A nephropathy, showing a significant reduction in urine protein levels. Nefecon is already approved in the U.S. as Tarpeyo, and the company continues to operate across various global segments providing a range of pharmaceutical products.
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now
Viatris Inc. (NASDAQ: VTRS) is highlighted as one of the most undervalued NASDAQ stocks, following positive top-line results from its Phase 3 clinical trial for VR-205 in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The treatment demonstrated a significant reduction in urine protein-to-creatinine ratio and improved kidney function, consistent with global studies. Viatris plans to submit a New Drug Application (NDA) in Japan by the end of 2026, aiming to offer the first IgAN-specific, targeted-release budesonide oral therapy in the country.
Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now
Viatris (VTRS) has announced positive top-line results from a Phase 3 clinical trial for VR-205, a treatment for primary immunoglobulin A nephropathy (IgAN) in Japanese adults, showing a significant reduction in urine protein-to-creatinine ratio. The company plans to submit a New Drug Application in Japan by the end of 2026, aiming to provide the first IgAN-specific oral therapy in the country. While acknowledging VTRS's investment potential, the article suggests that certain AI stocks may offer greater upside and less downside risk.
10 Most Undervalued NASDAQ Stocks to Buy Right Now
This article identifies Diamondback Energy Inc. (NASDAQ: FANG) as one of the 10 most undervalued NASDAQ stocks to buy right now. It highlights the recent acquisition by its subsidiary, Viper Energy, of mineral and royalty interests, expanding its presence in the Permian Basin. Diamondback Energy is an independent American oil and natural gas company focused on unconventional onshore oil and gas reserves in West Texas.
ESPR - Esperion Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Esperion Therapeutics Inc (ESPR), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, short interest, and volatility metrics, alongside analyst recommendations and target prices. The data aims to offer a comprehensive snapshot of the company's financial health and market position.
10 Most Undervalued NASDAQ Stocks to Buy Right Now
This article lists the 10 most undervalued NASDAQ stocks, focusing on Diamondback Energy Inc. (NASDAQ: FANG) as an example. It highlights the recent acquisition by its subsidiary, Viper Energy, which is expanding its mineral and royalty holdings in the Permian Basin. The piece emphasizes Diamondback Energy's focus on unconventional oil and gas reserves in West Texas.
GRFS - Grifols SA ADR Short Interest
This article provides a detailed overview of Grifols SA ADR (GRFS) stock, focusing on its short interest and various financial metrics. It includes data on market capitalization, income, sales, dividends, P/E ratio, EPS growth, insider and institutional ownership, profitability margins, and price performance over different periods. The stock closed at $7.16, showing a slight increase, with a short float of 2.33% and a short interest of 6.01 million shares.
If You Invested $1,000 in Lexicon Pharmaceuticals Inc (LXRX)
This article examines the historical performance of investing $1,000 in Lexicon Pharmaceuticals Inc (LXRX) over one, five, and ten years, comparing its returns to the S&P 500. It also provides an in-depth profile of Lexicon Pharmaceuticals, detailing its biopharmaceutical products, key pipeline assets like sotagliflozin and pilavapadin, strategic collaborations, and financial information. The company focuses on cardiometabolic and neurological conditions through its Genome5000™ genomics-based discovery platform.
TBPH SEC Filings - Theravance Bioph 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Theravance Biopharma (TBPH) SEC filings, including 10-K, 10-Q, and 8-K reports, as well as insider trading forms. Recent filings detail equity grants to executives, a patent settlement for YUPELRI® extending generic availability to 2039, and the company's strategic restructuring and evaluation of alternatives following the ampreloxetine program wind-down, aiming to significantly reduce operating expenses. The detailed entries offer AI-generated summaries, impact scoring, and sentiment analysis for each filing.
GRFS - Grifols SA ADR Volatility & Greeks
This article provides a comprehensive financial overview of Grifols SA ADR (GRFS), detailing its stock performance, volatility, and key financial ratios. It includes data on market capitalization, income, sales, dividend information, and analyst recommendations. The report also highlights insider and institutional ownership, short interest, and various profitability margins.
Arthur Cox advises on pharmaceutical sector acquisition
Irish law firm Arthur Cox advised Theravance Biopharma on its acquisition by biotechnology company Zymeworks Inc. The deal, valued at $929 million in equity, will see Theravance Biopharma shareholders receive cash and a contingent value right for future proceeds. This transaction follows a strategic review and aims to maximize shareholder value.
GRFS - Grifols SA ADR Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Grifols SA ADR (GRFS). It covers key financial figures like market cap, income, sales, and various ratios, along with stock performance metrics, insider ownership, analyst recommendations, and recent SEC filing information.
VTRS - Viatris Inc Options
This page provides a detailed financial overview of Viatris Inc. (VTRS), including its key financial metrics, stock performance, insider and institutional ownership, and various valuation ratios. It covers data such as market capitalization, sales, earnings per share, dividend information, and short interest, offering a comprehensive snapshot of the company's current financial health and market position.
Viatris Inc. stock rises Thursday, outperforms market
Viatris Inc. (VTRS) stock increased by 3.21% to close at $16.70 on Thursday, outperforming the broader market. This rise marked the stock's second consecutive day of gains. The S&P 500 Index remained mostly unchanged, while the Dow Jones Industrial Average saw a 1.14% increase.
GRFS - Grifols SA ADR Forecast, Target Price
This article provides a detailed financial overview and forecast for Grifols SA ADR (GRFS), including key financial metrics, performance indicators, and analyst target prices. It highlights the company's current stock price, dividend information, various valuation ratios, and performance over different timeframes. The data suggests a target price of $14.43 against a last close of $7.16, indicating potential upside according to the provided metrics.
Viatris Refinances $247.7 Million Term Loan
Viatris has successfully refinanced a $247.7 million term loan. This strategic financial maneuver is aimed at optimizing the company's debt structure and potentially reducing interest expenses. The refinancing operation reflects Viatris's ongoing efforts to manage its financial obligations efficiently.
Should WisdomTree U.S. MidCap Dividend ETF (DON) Be on Your Investing Radar?
The WisdomTree U.S. MidCap Dividend ETF (DON) is a passively managed fund providing exposure to the Mid Cap Value segment of the U.S. equity market, with over $3.97 billion in assets and an expense ratio of 0.38%. It primarily invests in the Financials sector and has shown a 10.55% gain year-to-date and 13.36% over the last year. The article suggests DON as a reasonable option for investors interested in mid-cap value, noting alternatives like IWS and VOE with lower expense ratios.
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris Inc. (Nasdaq: VTRS) announced it will report its second-quarter 2026 financial results on Thursday, August 6, 2026. The global healthcare company will host a conference call and live webcast at 8:30 a.m. ET on the same day to discuss the results, with investors able to access it via their investor relations website or by phone. A replay of the webcast will also be available online.
Viatris Inc. stock rises Wednesday, outperforms market
Viatris Inc. (VTRS) stock rose 1.89% on Wednesday to $16.18, outperforming the broader market which saw the S&P 500 Index fall 0.22% and the Dow Jones Industrial Average fall 0.03%. This rise broke a two-day losing streak for the company's stock.
Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees
Viatris Inc. director Leo Frans Groothuis received 2,756 deferred stock units (DSUs) on June 30, 2026, as compensation instead of cash fees. Each DSU represents one share of Viatris common stock, valued at $15.88 per share, and is fully vested. These units will be delivered upon future events such as termination of service, death, disability, or a change in control.
Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as fees
Viatris director David S. Simmons was granted 2,362 deferred stock units (DSUs) on June 30, 2026, as compensation for his quarterly non-employee director fees. These DSUs, valued at $15.88 per share, are fully vested and will settle into Viatris common stock upon his termination of service, death, disability, or a change in control of the company. This transaction was reported in a Form 4 filing and represents an equity-based form of compensation.
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility
Viatris has secured a new ¥40 billion senior unsecured three-year term loan from Mizuho Bank to refinance its existing 2021 facility of the same amount. The loan will be used for general corporate purposes, bears interest initially at the TIBO rate plus 1.10%, and includes standard covenants with a maximum leverage ratio of 3.75x. The agreement was signed and became effective on July 1, 2026.
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility
Viatris has secured a new ¥40 billion senior unsecured three-year term loan with Mizuho Bank, which will be used to refinance its existing 2021 facility and for general corporate purposes. The loan bears interest at the TIBO rate plus 1.10%, with the margin adjustable based on the company's debt ratings. The agreement includes customary covenants, such as a maximum leverage ratio of 3.75x.
Viatris - Enters Amended And Restated Term Loan Credit Agreement On July 1, 2026 - SEC Filing
Viatris has announced it entered into an amended and restated term loan credit agreement on July 1, 2026. This information was disclosed in an SEC filing. The full details are available through TradingView News Search, sourced from Refinitiv.
Viatris (NASDAQ: VTRS) signs ¥40B three-year unsecured term loan deal
Viatris Inc. has secured a new ¥40 billion three-year unsecured term loan facility, replacing a prior facility of the same amount. The company will use the funds for general corporate purposes, including the repayment of its 2021 term loan. This new facility bears interest at the TIBO Rate plus 1.10% and includes customary covenants, such as a leverage ratio not exceeding 3.75 to 1.00.
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris Inc. will announce its second-quarter 2026 financial results on Thursday, August 6, 2026. The company will host a conference call and live webcast on the same day at 8:30 a.m. ET to discuss the financial outcomes. Investors and the public can access the webcast or call in to listen to the presentation.
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205
Viatris Inc. (VTRS) announced positive Phase 3 results in Japan for VR-205 (Nefecon), a treatment for primary IgA nephropathy, showing significant proteinuria reductions and kidney function improvements. These results align with global findings and support a planned New Drug Application in Japan by the end of 2026, potentially strengthening Viatris's shift towards branded, higher-value therapies. While this data offers a nearer-term boost to its pipeline, persistent pricing pressure on its generics portfolio remains a key risk.
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris Inc. (Nasdaq: VTRS) announced it will report its second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET to discuss the results, with investors and the public invited to listen via webcast or phone. A replay will also be available on the company's investor website.
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris Inc. announced it will report its second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET on the same date to discuss the results. Interested parties can access the webcast or call in to listen to the discussion.
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris Inc. (Nasdaq: VTRS) announced it will report its second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET on the same day to discuss these results. Investors and the public can access the webcast or call in to listen.
Zymeworks to acquire Theravance Biopharma in deal worth $929m
Zymeworks has announced its acquisition of Theravance Biopharma in a deal valued at approximately $929 million. This strategic move grants Zymeworks ownership of Yupelri, a key treatment for Chronic Obstructive Pulmonary Disease (COPD), broadening its portfolio. The acquisition aligns with Zymeworks' goal of diversifying its business through a combination of partner-driven cash flows and innovative R&D.
VTRS - Viatris Inc Latest SEC Filings
This article provides a detailed financial overview and snapshot of Viatris Inc. (VTRS) based on its latest SEC filings. It includes key financial metrics such as market cap, enterprise value, sales, earnings per share, dividend information, and various performance indicators. The data also covers analyst recommendations, insider ownership, institutional ownership, and short interest figures.
Viatris Inc. stock falls Tuesday, underperforms market
Viatris Inc. (VTRS) stock fell 2.16% on Tuesday, closing at $15.88. This underperformed the broader market, as both the S&P 500 Index and the Dow Jones Industrial Average saw gains. This marked the second consecutive day of losses for Viatris.
Canadian Zymeworks acquires American Theravance Biopharma for $929 million
Canadian biotech company Zymeworks Inc. has agreed to acquire American Theravance Biopharma Inc. for $929 million, with the transaction expected to close in the second half of 2026. This acquisition supports Zymeworks' strategy to diversify its portfolio and optimize product value, including profiting from the sale of the Yupelri drug for chronic lung disease and acquiring Theravance's research and development assets.
Theravance Stock Down 3% After Zymeworks Announces Buyout
Theravance Biopharma's stock dropped 3% after announcing an all-cash acquisition by Zymeworks Inc. for approximately $929 million. The deal follows a strategic review by Theravance after its lead candidate, ampreloxetine, failed in a pivotal phase III study. Shareholders will receive $17.00 per share plus a contingent value right for 80% of future net proceeds from ampreloxetine's monetization.
(VTRS) Risk Channels and Responsive Allocation
The article provides a detailed analysis of Viatris Inc. (NASDAQ: VTRS), highlighting strong near-term sentiment that could lead to a long-term positive bias. It identifies a significant 29.8:1 risk-reward setup targeting a 9.2% gain against 0.3% risk. The analysis also outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, based on AI models.
B. Riley reiterates buy on Zymeworks stock after Theravance acquisition
B. Riley has reiterated its "buy" rating and $40 price target for Zymeworks Inc. following the company's announcement to acquire Theravance Biopharma Inc. The acquisition, valued at approximately $929 million in equity, includes Theravance's YUPELRI product and is expected to close in the second half of 2026. Analysts from BTIG, Stifel, and H.C. Wainwright have also provided ratings and targets for both companies in light of this strategic move and recent clinical data for Zymeworks' pipeline.
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma
This article details two significant pharmaceutical acquisitions: Zymeworks' agreement to acquire Theravance Biopharma for approximately $929 million, primarily for its commercial COPD asset Yupelri and Irish tax attributes, and Ipsen's plan to acquire Kartos Therapeutics for up to $1.75 billion, adding the investigational MDM2 inhibitor navtemadlin to its oncology pipeline. Both deals aim to strengthen the acquirers' commercial portfolios and R&D pipelines, with Zymeworks focusing on profitability and Ipsen on late-stage oncology assets.
Viatris reports positive phase 3 results for IgAN drug in Japan
Viatris Inc. announced positive Phase 3 clinical trial results for VR-205, its targeted-release budesonide formulation, in Japanese adult patients with primary IgA nephropathy (IgAN). The study met its primary endpoint, showing a statistically significant reduction in urine protein-to-creatinine ratio, and the drug was well-tolerated. Viatris plans to submit a New Drug Application in Japan by the end of 2026 for VR-205, which is already approved in the U.S. and Europe.
Viatris reports positive phase 3 results for IgAN drug in Japan
Viatris Inc. announced positive Phase 3 clinical trial results for its targeted-release budesonide formulation, VR-205, in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN). The trial met its primary endpoint, showing a significant reduction in urine protein-to-creatinine ratio, with the drug generally well tolerated. Viatris plans to submit a New Drug Application in Japan by the end of 2026, leveraging a licensing agreement with Calliditas Therapeutics AB.
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
Viatris Inc. announced positive top-line results from a Phase 3 clinical trial evaluating VR-205 (targeted-release budesonide formulation) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN). The study met its primary endpoint, showing a statistically significant and clinically meaningful reduction in urine protein-to-creatinine ratio (UPCR) and demonstrating a safety profile consistent with global studies. Viatris aims to submit a New Drug Application in Japan by the end of 2026, where IgAN is highly prevalent and there is a significant unmet need for disease-modifying treatments.
Zymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks Inc. announced a definitive agreement to acquire Theravance Biopharma, Inc. for $17.00 per share, approximately $929 million. The acquisition will add YUPELRI® (revefenacin), a treatment for COPD, to Zymeworks' portfolio, anticipated to generate around $60 million in annualized cash flow. The transaction is structured with a $350 million non-recourse note from OMERS Life Sciences and Theravance's cash, with Zymeworks contributing $219 million.
Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny
Indivior's Nasdaq listing is under analyst scrutiny, with a clear consensus forming around its earnings and valuation. This analysis focuses on how forecasts, ratings, and the sector context influence the risk-reward profile for retail investors. The company, known for its buprenorphine-based prescription drugs for opioid dependence, is covered by several international financial houses, primarily tracking its U.S. listing as Indivior Pharmaceuticals Inc. on Nasdaq.
Join Class Action to Recover Losses from Viatris Inc. (VTRS) - Contact Levi & Korsinsky Before June 3, 2025
Levi & Korsinsky LLP announced a class action lawsuit against Viatris Inc. (NASDAQ: VTRS) for alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of a warning letter from the FDA concerning its Indore, India facility, leading to a significant stock price drop following disappointing 2025 guidance. Shareholders who suffered losses during this period are encouraged to contact the firm before June 3, 2025, to learn about recovery options.
Form 4 Viatris Inc For: 26 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Viatris Inc. (VTRS) that occurred on June 26. The piece itself is very brief and primarily serves as an announcement for this regulatory filing, indicating insider trading activity.
Enterprise value to EBITDA forward of Viatris Inc. – NASDAQ:VTRS
The article focuses on the enterprise value to EBITDA forward metric for Viatris Inc. (NASDAQ: VTRS). It appears to be a financial data point presented within a trading platform context.
Enterprise value to revenue forward of Viatris Inc. – NASDAQ:VTRS
This article provides financial context for Viatris Inc. (NASDAQ: VTRS), specifically focusing on its enterprise value to revenue forward. It is a brief financial snippet from TradingView, offering a quick look at this key metric for the pharmaceutical company.
Price to earnings forward of Viatris Inc. – NASDAQ:VTRS
This article provides financial information for Viatris Inc. (NASDAQ: VTRS), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed, and data is provided by ICE Data Services and FactSet.
Form 4 Viatris Inc For: 26 June By Investing.com
This article from Investing.com is a brief report indicating a Form 4 filing for Viatris Inc. on June 26th. It provides no further details beyond the title and company name, focusing on the administrative filing.
Viatris interim CFO Paul Campbell sells $809,784 in stock By Investing.com
Paul Campbell, interim CFO of Viatris Inc. (NASDAQ:VTRS), sold 50,076 shares of company stock for $809,784 on June 25, 2026. This transaction was part of a Rule 10b5-1 trading plan and occurred while Viatris shares are near their 52-week high after an 83% one-year return. Despite the sale, Campbell still directly holds 316,212 shares, and the stock is considered undervalued according to InvestingPro.
